Recent subgroup analysis data from the Chinese population has revealed new treatment strategies for relapsed/refractory multiple myeloma. Results from the international multicenter DREAMM-7 study involving Chinese researchers show that an innovative BCMA-targeted antibody-drug conjugate (ADC) therapy, combining monoclonal antibodies with bortezomib and dexamethasone (B-Vd regimen), demonstrates higher complete response (CR) rates, improved objective response rates (ORR), longer progression-free survival (PFS), and overall survival (OS) benefits compared to current standard treatments for Chinese patients with relapsed/refractory conditions. This not only provides crucial evidence for global multiple myeloma treatment but also represents another significant milestone in China’s transition from “follower” to “leader” in multiple myeloma clinical research.
Multiple myeloma ranks as the second most common hematologic malignancy. With China’s aging population accelerating, its incidence rate is steadily increasing. “The annual incidence of multiple myeloma in China is approximately 1-2 cases per 100,000 people. While this figure may seem low, the large population base translates to over 17,000 new cases annually.
